Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Ono Sets Up Investigation Panel on Bribery Issue
Two Ono Pharmaceutical employees were indicted on February 17 for bribery charges by the Tsu District Public Prosecutor’s Office, the company said the same day, revealing that it has already set up an investigation committee to look into the cause…
To read the full story
Related Article
- Maker FTC Issues “Warning” to Ono over Onoact Bribery Case
December 16, 2021
- Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
- Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Jail Terms Sought for 2 Ono Employees over Onoact-Tied Bribery Charges
June 1, 2021
- 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…